Welcome to our dedicated page for AstraZeneca news (Ticker: AZN), a resource for investors and traders seeking the latest updates and insights on AstraZeneca stock.
AstraZeneca PLC develops and commercializes prescription medicines across oncology, rare diseases, and BioPharmaceuticals, including cardiovascular, renal and metabolism, respiratory, and immunology. News about AZN commonly covers clinical-trial results, FDA and advisory-committee actions, product approvals, and updates to marketed medicines such as TRUQAP, BREZTRI, SAPHNELO, IMFINZI, IMJUDO, and ULTOMIRIS.
Company updates also address quarterly revenue and earnings trends, alliance and collaboration revenue, licensing transactions for pipeline assets, and governance changes. Recurring development themes include targeted oncology, COPD, asthma, systemic lupus erythematosus, liver cancer, prostate cancer, and rare or immune-mediated diseases.
Rhea-AI Summary
AstraZeneca's SERENA-6 Phase III trial demonstrated significant success for camizestrant in treating HR-positive breast cancer. The drug, combined with CDK4/6 inhibitors, reduced disease progression or death risk by 56% compared to standard treatment, with median progression-free survival of 16.0 months versus 9.2 months. The trial marked the first use of circulating tumor DNA monitoring to detect and treat emerging resistance before disease progression. Camizestrant also improved quality of life metrics, delaying deterioration by 23.0 months compared to 6.4 months with standard treatment. The safety profile was consistent with known profiles, though Grade 3 adverse events were higher in the camizestrant arm (60% vs 46%). Based on these results, the FDA granted Breakthrough Therapy Designation for camizestrant in combination with CDK4/6 inhibitors for HR-positive, HER2-negative advanced breast cancer patients with ESR1 mutations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.24%
Tags
-
Rhea-AI Summary
AstraZeneca and Daiichi Sankyo's ENHERTU demonstrated superior efficacy in the DESTINY-Gastric04 phase 3 trial for second-line HER2-positive gastric cancer treatment. The drug showed a 30% reduction in death risk compared to ramucirumab plus paclitaxel, with median overall survival of 14.7 vs 11.4 months. ENHERTU achieved significant improvements across key metrics: 26% reduction in disease progression risk, 44.3% objective response rate (vs 29.1%), and 7.4 months median duration of response (vs 5.3 months). The safety profile remained consistent with previous trials, though interstitial lung disease occurred in 13.9% of ENHERTU patients, mostly low-grade. These results position ENHERTU as a potential global standard of care for second-line treatment in HER2-positive gastric cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.24%
Tags
-
Rhea-AI Summary
Danaher (NYSE: DHR) has announced a strategic partnership with AstraZeneca (LSE/STO/Nasdaq: AZN) to develop and commercialize advanced diagnostic tools for precision medicine. The collaboration will leverage Danaher's Centers for Enabling Precision Medicine and technology from its subsidiary, Leica Biosystems, focusing initially on digital and computational pathology products with AI-assisted algorithms.
The partnership aims to create diagnostic tests that help identify patients most likely to benefit from targeted therapies. Leica Biosystems will utilize its global laboratory network to deploy these tests worldwide, supported by its commitment to open-access DICOM standards for enhanced workflow connectivity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.77%
Tags
Rhea-AI Summary
AstraZeneca will present significant clinical trial data at the 2025 ASCO Annual Meeting (May 30-June 3), marking its seventh consecutive year with plenary presentations. The company will showcase over 80 abstracts featuring 20 medicines, including two plenary presentations. Key highlights include the SERENA-6 Phase III trial of camizestrant for HR-positive breast cancer, MATTERHORN Phase III trial of IMFINZI for gastric cancer, and DESTINY-Breast09 Phase III trial of ENHERTU for HER2-positive metastatic breast cancer. The SERENA-6 trial is notably the first positive Phase III trial for a next-generation oral SERD in first-line setting, while DESTINY-Breast09 is the first trial in over a decade showing superiority over first-line standard care in HER2-positive metastatic patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.34%
Tags
-
Rhea-AI Summary
AstraZeneca's AIRSUPRA demonstrated exceptional results in the Phase IIIb BATURA trial for mild asthma treatment. The study showed a 47% reduction in severe exacerbation risk compared to albuterol alone (5.1% vs 9.1%, p0.001). The trial was stopped early due to overwhelming efficacy. Key findings include a in systemic corticosteroid exposure and consistent safety profile with albuterol. AIRSUPRA is the first FDA-approved anti-inflammatory rescue medication for as-needed treatment in asthma patients 18 and older. The results, published in the New England Journal of Medicine and presented at ATS 2025, support AIRSUPRA as a potential new standard of care, particularly significant for mild asthma patients who represent 50-70% of cases and account for up to 30% of asthma-related exacerbations and deaths.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.28%
Tags
-
Rhea-AI Summary
AstraZeneca (AZN) will present over 75 abstracts, including 8 late-breakers, at the American Thoracic Society (ATS) International Conference from May 16-21, 2025. The presentations focus on their respiratory portfolio targeting asthma, COPD, and other inflammatory diseases. Key highlights include:
- AIRSUPRA data showing potential as preferred rescue treatment across all asthma severities
- BREZTRI studies demonstrating impact on cardiopulmonary outcomes in COPD patients
- FASENRA research in EGPA treatment and eosinophilic inflammation
- TEZSPIRE data on severe asthma and chronic rhinosinusitis
- Early-stage pipeline developments including AI/machine learning applications in respiratory disease research
The company aims to transform respiratory care, addressing COPD as the third leading cause of death worldwide and targeting unmet needs in asthma treatment.Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.78%
Tags
Rhea-AI Summary
AstraZeneca's IMFINZI® (durvalumab) demonstrated significant success in a Phase III POTOMAC trial for treating high-risk non-muscle-invasive bladder cancer (NMIBC). The study showed that one year of IMFINZI treatment combined with standard BCG therapy significantly improved disease-free survival (DFS) compared to BCG therapy alone. This is particularly significant as over 70% of bladder cancer patients are diagnosed with NMIBC, and about half are classified as high-risk. Currently, 80% of patients experience disease recurrence, with almost half potentially requiring bladder removal surgery. The safety profile was consistent with known data, and the addition of IMFINZI did not compromise BCG therapy completion. However, a second experimental arm testing IMFINZI plus BCG induction-only therapy did not meet the DFS endpoint.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.4%
Tags
-
Rhea-AI Summary
AstraZeneca and Daiichi Sankyo announced positive Phase III trial results for ENHERTU in treating high-risk HER2-positive early-stage breast cancer. The DESTINY-Breast11 trial demonstrated that ENHERTU followed by THP showed a statistically significant improvement in pathologic complete response (pCR) rate compared to standard treatment. The trial also revealed an improved safety profile versus standard of care, with early positive trends in event-free survival. This marks the first Phase III trial showing ENHERTU's benefit in early breast cancer, potentially challenging current treatment standards. The safety profile was consistent with known data, and interstitial lung disease rates were similar across treatment arms. Notably, approximately one in three patients with early-stage breast cancer are considered high risk, and nearly half of patients receiving current neoadjuvant treatment do not achieve pCR.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.27%
Tags
-
Rhea-AI Summary
AstraZeneca and Daiichi Sankyo announced positive Phase 3 trial results for ENHERTU® in treating high-risk HER2-positive early-stage breast cancer. The DESTINY-Breast11 trial demonstrated that ENHERTU followed by THP showed a statistically significant improvement in pathologic complete response (pCR) compared to standard treatment when used before surgery. The study revealed an improved safety profile versus standard care, with similar rates of interstitial lung disease across treatment arms. Early event-free survival data showed a positive trend favoring ENHERTU. This marks the first Phase 3 trial demonstrating ENHERTU's benefit in early breast cancer, potentially challenging current treatment standards. Approximately one-third of early-stage breast cancer patients are considered high-risk, with current treatments achieving pCR in only about half of patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.27%
Tags
Rhea-AI Summary
AstraZeneca's BREZTRI AEROSPHERE achieved significant success in Phase III KALOS and LOGOS trials for uncontrolled asthma treatment. The trials demonstrated statistically significant and clinically meaningful improvement in lung function compared to dual-combination ICS/LABA medicines. The study included approximately 4,400 randomized patients, evaluating BREZTRI's 320/28.8/9.6μg dose. This development is particularly significant as 262 million people worldwide are affected by asthma, with nearly half of those on dual therapy remaining uncontrolled. BREZTRI, already approved for COPD treatment in over 80 countries, showed no new safety or tolerability concerns during these trials. The positive results position BREZTRI as a potential new treatment option for asthma patients who remain uncontrolled with current dual maintenance therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.74%
Tags
FAQ
What is the current stock price of AstraZeneca (AZN)?
The current stock price of AstraZeneca (AZN) is $189.28 as of July 8, 2026.
What is the market cap of AstraZeneca (AZN)?
The market cap of AstraZeneca (AZN) is approximately 299.5B.